Systemic Therapy for Melanoma : ASCO Guideline Update
PURPOSE: To provide guidance to clinicians regarding the use of systemic therapy for melanoma.
METHODS: American Society of Clinical Oncology convened an Expert Panel and conducted an updated systematic review of the literature.
RESULTS: The updated review identified 21 additional randomized trials.
UPDATED RECOMMENDATIONS: Neoadjuvant pembrolizumab was newly recommended for patients with resectable stage IIIB to IV cutaneous melanoma. For patients with resected cutaneous melanoma, adjuvant nivolumab or pembrolizumab was newly recommended for stage IIB-C disease and adjuvant nivolumab plus ipilimumab was added as a potential option for stage IV disease. For patients with unresectable or metastatic cutaneous melanoma, nivolumab plus relatlimab was added as a potential option regardless of BRAF mutation status and nivolumab plus ipilimumab followed by nivolumab was preferred over BRAF/MEK inhibitor therapy. Talimogene laherparepvec is no longer recommended as an option for patients with BRAF wild-type disease who have progressed on anti-PD-1 therapy. Ipilimumab- and ipilimumab-containing regimens are no longer recommended for patients with BRAF-mutated disease after progression on other therapies.This full update incorporates the new recommendations for uveal melanoma published in the 2022 Rapid Recommendation Update.Additional information is available at www.asco.org/melanoma-guidelines.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
|---|---|
| Enthalten in: |
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 41(2023), 30 vom: 20. Okt., Seite 4794-4820 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Seth, Rahul [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
31YO63LBSN |
|---|
| Anmerkungen: |
Date Completed 27.11.2023 Date Revised 13.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1200/JCO.23.01136 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36078609X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36078609X | ||
| 003 | DE-627 | ||
| 005 | 20231227131453.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1200/JCO.23.01136 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1225.xml |
| 035 | |a (DE-627)NLM36078609X | ||
| 035 | |a (NLM)37579248 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Seth, Rahul |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Systemic Therapy for Melanoma |b ASCO Guideline Update |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.11.2023 | ||
| 500 | |a Date Revised 13.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a PURPOSE: To provide guidance to clinicians regarding the use of systemic therapy for melanoma | ||
| 520 | |a METHODS: American Society of Clinical Oncology convened an Expert Panel and conducted an updated systematic review of the literature | ||
| 520 | |a RESULTS: The updated review identified 21 additional randomized trials | ||
| 520 | |a UPDATED RECOMMENDATIONS: Neoadjuvant pembrolizumab was newly recommended for patients with resectable stage IIIB to IV cutaneous melanoma. For patients with resected cutaneous melanoma, adjuvant nivolumab or pembrolizumab was newly recommended for stage IIB-C disease and adjuvant nivolumab plus ipilimumab was added as a potential option for stage IV disease. For patients with unresectable or metastatic cutaneous melanoma, nivolumab plus relatlimab was added as a potential option regardless of BRAF mutation status and nivolumab plus ipilimumab followed by nivolumab was preferred over BRAF/MEK inhibitor therapy. Talimogene laherparepvec is no longer recommended as an option for patients with BRAF wild-type disease who have progressed on anti-PD-1 therapy. Ipilimumab- and ipilimumab-containing regimens are no longer recommended for patients with BRAF-mutated disease after progression on other therapies.This full update incorporates the new recommendations for uveal melanoma published in the 2022 Rapid Recommendation Update.Additional information is available at www.asco.org/melanoma-guidelines | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Practice Guideline | |
| 650 | 4 | |a Systematic Review | |
| 650 | 7 | |a Ipilimumab |2 NLM | |
| 650 | 7 | |a Nivolumab |2 NLM | |
| 650 | 7 | |a 31YO63LBSN |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Proteins B-raf |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 650 | 7 | |a relatlimab |2 NLM | |
| 700 | 1 | |a Agarwala, Sanjiv S |e verfasserin |4 aut | |
| 700 | 1 | |a Messersmith, Hans |e verfasserin |4 aut | |
| 700 | 1 | |a Alluri, Krishna C |e verfasserin |4 aut | |
| 700 | 1 | |a Ascierto, Paolo A |e verfasserin |4 aut | |
| 700 | 1 | |a Atkins, Michael B |e verfasserin |4 aut | |
| 700 | 1 | |a Bollin, Kathryn |e verfasserin |4 aut | |
| 700 | 1 | |a Chacon, Matias |e verfasserin |4 aut | |
| 700 | 1 | |a Davis, Nancy |e verfasserin |4 aut | |
| 700 | 1 | |a Faries, Mark B |e verfasserin |4 aut | |
| 700 | 1 | |a Funchain, Pauline |e verfasserin |4 aut | |
| 700 | 1 | |a Gold, Jason S |e verfasserin |4 aut | |
| 700 | 1 | |a Guild, Samantha |e verfasserin |4 aut | |
| 700 | 1 | |a Gyorki, David E |e verfasserin |4 aut | |
| 700 | 1 | |a Kaur, Varinder |e verfasserin |4 aut | |
| 700 | 1 | |a Khushalani, Nikhil I |e verfasserin |4 aut | |
| 700 | 1 | |a Kirkwood, John M |e verfasserin |4 aut | |
| 700 | 1 | |a McQuade, Jennifer Leigh |e verfasserin |4 aut | |
| 700 | 1 | |a Meyers, Michael O |e verfasserin |4 aut | |
| 700 | 1 | |a Provenzano, Anthony |e verfasserin |4 aut | |
| 700 | 1 | |a Robert, Caroline |e verfasserin |4 aut | |
| 700 | 1 | |a Santinami, Mario |e verfasserin |4 aut | |
| 700 | 1 | |a Sehdev, Amikar |e verfasserin |4 aut | |
| 700 | 1 | |a Sondak, Vernon K |e verfasserin |4 aut | |
| 700 | 1 | |a Spurrier, Gilliosa |e verfasserin |4 aut | |
| 700 | 1 | |a Swami, Umang |e verfasserin |4 aut | |
| 700 | 1 | |a Truong, Thach-Giao |e verfasserin |4 aut | |
| 700 | 1 | |a Tsai, Katy K |e verfasserin |4 aut | |
| 700 | 1 | |a van Akkooi, Alexander |e verfasserin |4 aut | |
| 700 | 1 | |a Weber, Jeffrey |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical oncology : official journal of the American Society of Clinical Oncology |d 1986 |g 41(2023), 30 vom: 20. Okt., Seite 4794-4820 |w (DE-627)NLM012608777 |x 1527-7755 |7 nnns |
| 773 | 1 | 8 | |g volume:41 |g year:2023 |g number:30 |g day:20 |g month:10 |g pages:4794-4820 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1200/JCO.23.01136 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 41 |j 2023 |e 30 |b 20 |c 10 |h 4794-4820 | ||